Irodalom:
1. Sangeet Ghai et al.: Primary gastrointestinal lymphoma: Spectrum of imaging findings with pathologic
correlation. RadioGraphics 2007; 27: 1371-1388.
2. LG Capelle et al.: Epidemiology of gastric malt lymphoma: A long-term nationwide study in the
netherlands. Gut 2008; 57 (Suppl II): A99.
3. P Isaacson: Update on MALT lymphomas. Best Practice & Research Clinical Haematology Volume 18;
1: 57-68.
4. M Van Domselaar et al.: Lymphoprolipherative disorders diagnosed in an inflammatory bowel disease
patient series. Gut 2008; 57 (Suppl II): A57.
5. S Hellmig et al.: A genetic variant in ATG16L1 has a protective effect in the development of primary
gastric B-cell lymphoma in H. pylori infected patients. Gut 2008; 57 (Suppl II): A99.
6. M Kawasaki et al.: Usefulness of single balloon enteroscopy for diagnosis in small intestinal disease.
Endoscopy 2008; 40 (Suppl 1): A405.
7. S Daum et al.: Double-balloon enteroscopy in patients with refractory sprue. Gut 2008; 57 (Suppl II): A223.
8. DY Cheung et al.: Diagnostic and therapeutic impact of capsule endoscopy on small intestinal tumors:
a korean multicenter study. Endoscopy 2008; 40 (Suppl 1): A306.
9. MJ Varas et al.: Endoscopic staging of low-grade gastric MALT lymphoma. Rev Esp Enterm Dig
(Madrid) 2006; 98 (3): 189-195.
10. Ioana G et al.: Computer tomographic evaluation of digestive tract non-Hodgkin lymphomas. Gastrointestin
Liver Dis 2007; 16 (3): 315-319.
11. LG Capelle et al.: High adenocarcinoma risk after diagnosis of gastric MALT lymphoma: a long-term
nationwide study. Gut 2008; 57 (Suppl II): A100.
12. P Basu et al.: Novel therapy for the non-responder population with H pylori – lend (levofloxacin,
esomeprazole, nitazoxanide and doxycycline) study. Gut 2008; 57 (Suppl II): A328.
13. T Hirashima et al.: Long-term outcomes of gastric mucosa-associated lymphoid tissue lymphomas
after helicobacter pylori eradication therapy. Gut 2008; 57 (Suppl II): A100.
14. A Rouskoné-Fourmestraux et al.: Radiotherapy in gastric MALT lymphoma non-responding to H.
pylori eradication. Gut 2008; 57 (Suppl II): A100.
Gastro 2009.qxd 5/9/2009 1:42 PM Page 482
Egyéb 483
15. I Fernandez-Balnco et al.: De novo fluminant colitis after rituximab therapy on a non-Hodgkin lymphoma.
Gut 2008; 57 (Suppl II): A250.
16. KE Smedby et al.: Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma
types other than enteropathy-type T cell lymphoma. Gut 2005; 54: 54-59.
17. A Al-toma et al.: Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma:
retrospective evaluation of single-centre experience. Gut 2007; 56: 1373-1378.
18. Wu Xl et al.: Protein expression and clinical significance of cyclooxygenase 2 and nuclear factor kappa
B in gastric mucosa-associated lymphoid tissue lymphoma. Zhonghua Wei Chang Vai Ke Za Zhi 2008;
11 (2): 163-166.
19. Mark J Bishton et al.: Combination chemotherapy followd by autologous stem cell transplant for
enteropathy-associated T cell lymphoma. British Journal of Haematology 2007; 136 (1): 111-113.
20. Troch M et al.: Chronic autoimmune thyroiditis (Hashimoto’s thyroiditis) in patients with MALT lymphoma.
Ann Oncol 2008; 11.
21. Vrieling C et al.: Long-term results of stomach-conserving therapy in gastric MALT lymphoma. Radiother
Oncol 2008; 14.
22. W Fischbach: Lymphoma-Staging and treatment. In: Intestinal Disorders Falk Symposium 164. Abstracts,
2008; pp. 49-51.
